Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

por Dulucq, Stéphanie, Nicolini, Franck E., Rea, Delphine, Cony-Makhoul, Pascale, Charbonnier, Aude, Escoffre-Barbe, Martine, Coiteux, Valérie, Lenain, Pascal, Rigal-Huguet, Françoise, Liu, Jixing, Guerci-Bresler, Agnès, Legros, Laurence, Ianotto, Jean-Christophe, Gardembas, Martine, Turlure, Pascal, Dubruille, Viviane, Rousselot, Philippe, Martiniuc, Juliana, Jardel, Henry, Johnson-Ansah, Hyacinthe, Joly, Bertrand, Henni, Tawfiq, Cayssials, Emilie, Zunic, Patricia, Berger, Marc G., Villemagne, Bruno, Robbesyn, Fanny, Morisset, Stephane, Mahon, François-Xavier, Etienne, Gabriel
Publicado 2022